All News

Check out important updates from the FDA for the week of April 29.

A lack of clarity around certain provisions of the Inflation Reduction Act has presented challenges to payers.

Two trials studying brexpiprazole in combination with sertraline "constitute one of the largest clinical development programs ever conducted in posttraumatic stress disorder (PTSD)."

Are you a Wookie with a mane to maintain or a scoundrel prone to nausea? You don’t have to traverse distant planets to find OTC recommendations that meet your needs—this guide has you covered.

A siloed approach to care can worsen patient outcomes, but collaboration between one health system specialty pharmacy and a manufacturer led to better patient care.

A review found that many guidelines that recommended pharmacogenetic testing were inconsistent between clinical associations.

Understanding the goals of each party is the first step to a successful collaboration.

Collaboration between health system specialty pharmacists and pharmaceutical manufacturers can benefit patients in the long run.

The rise of weight-loss drugs has overtaken the US prescription drug market and significantly increased spending from 2022 to 2023.

Addressing requirements around FDA interchangeability designations can increase the adoption of biosimilar substitutions at the pharmacy level.

A recent bill introduced to Congress is intended to prevent product hopping, a practice that extends exclusivity and hinders the adoption of biosimilar therapies.

Distributors can help manufacturers create patient access programs that reduce costs, copays, and co-insurance.

One notable incentive includes the launch of biosimilars at both low- and high wholesale acquisition costs.

The organization has renewed its recommendation of Prescryptive Health’s artificial intelligence pricing system, stating it can help independent pharmacies stay competitive.

According to Michael Osso, president and chief executive officer of the Crohn’s & Colitis Foundation, “the flexibility of having multiple biosimilar formulations to choose from is important to support broader patient access to biologic medicine.”

In a testimony to the Senate Finance Committee, Andrew Witty discussed what led to the February Change Healthcare cyberattack and the organization’s response.

Pharmacists can help financial decision makers understand the value of biosimilar therapies.

Although the US Drug Enforcement Agency's (DEA) proposed reclassification of marijuana wouldn’t legalize the drug nationwide, it could shake up the current marijuana landscape.

Savings associated with biosimilar uptake are projected to reach $181 billion through 2027.

The role of health care specialty pharmacies has expanded.

Check out this list of our 10 most read stories from April 2024.

Pemivibart will act as an additional preventive option for COVID-19 among moderately-to-severely immunocompromised adult and adolescent patients, who are disproportionally impacted by the condition.

The expertise of health system specialty pharmacists, combined with better adherence and better affordability, leads to better patient outcomes.

Paying for these new therapies, that may be curative for patients, remains a challenge.

“I think in those situations where you can use the lower cost of the drug, you should, because it's going to help the overall societal perspective. That begins to break down, though, when that low-cost drug is the one that you're losing money on,” said Scott Soefje in a Q&A on balancing cost and margin at a site of care.

Researchers aimed to evaluate the efficacy of the OpenAI technology and offer guidance into its future implementation within health care services.

From medication adherence to patient counseling, clinical pharmacists at health system specialty pharmacies can play a role in reducing health care costs.

Recent research on COVID-19 vaccination shows that vaccines help fight variants, led to lower cases among children in California, and that boosters provide longer lasting protection.